Satellite Banner
Informatics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Optibrium Goes from Strength to Strength as Global Customer Base Continues to Grow

Published: Friday, September 21, 2012
Last Updated: Friday, September 21, 2012
Bookmark and Share
Company celebrates growth in all areas of the company as it enters its fourth year of business.

Optibrium has revealed a period of growth across all areas of its business.  Optibrium is celebrating significant expansion in its team of experts, requiring relocation to new, larger premises.  This success is built on the rapidly expanding, global customer base for Optibrium’s primary product, StarDrop. This pioneering drug discovery software platform offers a range of intuitive tools and technologies that guide the selection and design of high quality compounds in drug discovery.

Optibrium, which was founded in 2009, now boasts a customer base of over 50 pharma, biotech and academic groups spread across the globe, including seven of the top ten pharmaceutical companies. All have been attracted by StarDrop; a highly visual and easy-to-use software package, which provides a unique environment for multi-parameter optimisation of candidate drugs. It includes an interactive designer that helps to explore optimisation strategies, guided by StarDrop’s unique Glowing Molecule visualisation. The suite is complemented by a range of plug-in modules that further expand its capabilities to quickly identify better molecules, thereby reducing costs and timelines and strengthening pipelines.  Reflecting the growth of the business, Optibrium has expanded its software development and support teams to maintain the high level of support provided to its users and this has required the company to move to office space which is 50% larger than its original premises.

The most recent appointment has seen Nick Foster join as Director of Business Development. Nick’s role will see him lead the development of new business opportunities for Optibrium’s products.  Nick has 20 years of experience within the life science industry and academia and joins Optibrium from BioFocus.  Nick’s successful track record in business development is complemented by his early scientific career, spent as an ADME/PK scientist working on drug discovery projects.

Nick comments, “I am delighted to be joining the Optibrium team.  The company has a fantastic reputation in the industry for its innovative products and offers a dynamic place to work.  I look forward to developing our customer base and being part of Optibrium’s continuing expansion and success.”

CEO Matt Segall comments, “Over the past three years our team has developed our product portfolio and introduced innovative approaches to drug discovery as we expanded our customer base. We have now reached a really exciting phase of rapid growth as the result of this hard work and this provides further inspiration to the whole team who are dedicated to finding ways to help scientists to optimise drug discovery.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Optibrium Signs Agreement for Global License of StarDrop
Company has announced that Janssen Research and Development has signed an agreement to license Optibrium’s StarDrop software.
Tuesday, May 24, 2016
BioSolveIT and Optibrium Sign Collaboration Agreement
Partnership will deliver a link between 2D and 3D design on medicinal chemists’ desktops.
Tuesday, October 20, 2015
Optibrium Appoints Head of North American Operations to Support Growing Demand
Appointment marks the opening of new office in Cambridge, MA.
Thursday, September 03, 2015
Optibrium and Certara Collaborate
Collaboration will see integration of Optibrium’s StarDrop and Certera’s D360 platform.
Tuesday, April 21, 2015
Optibrium and ChemAxon Collaborate
Interface between StarDrop and Plexus facilitates seamless access to both software platforms.
Wednesday, April 15, 2015
Optibrium and NextMove Software Announce Technology Collaboration
Automatic application of Matsy method for matched series analysis within StarDrop™ will guide compound optimization in drug discovery.
Friday, January 16, 2015
Optibrium Appoints Director of Computational Chemistry
Appointment of Dr Peter Hunt represents part of further growth across all areas of its business.
Tuesday, April 29, 2014
Optibrium Joins HeCaToS Project and Expands R&D Team
The Hepatic and Cardiac Toxicity Systems project is a major European project with the objective to efficiently investigate the health impact of compounds on the heart and liver.
Tuesday, October 08, 2013
Optibrium and Cresset Announce Technology Collaboration
Technology exchange combines unique methods for design of novel, high quality compounds in drug discovery.
Thursday, January 05, 2012
Optibrium Showcases StarVue at ACS Spring 2010
Offering an Innovative Free Way to Explore Compound Data for Drug Discovery
Thursday, February 18, 2010
Scientific News
Emerging Model of Cancer
Cancer acts cooperatively, making individual decisions but acting in unison; this insight is being used to create a computer model of cancer.
Personalised Medicine: Dose by Design
Personalised medicine holds the promise of a new approach to healthcare, tailored exactly to our individual needs, as Congenica's Nick Lench discussed on a recent BBC Radio 4 programme.
Expanding Knowledge of Viral Diversity
Environmental datasets help researchers double the number of microbial phyla known to be infected by viruses.
Computers Better Predict Lung Cancer Type, Severity
Study shows automating the analysis of cancer tissue samples increases the accuracy of tumor classification and patient prognoses.
Using Big Data to Discover Potential Cancer Biomarkers
University of Hawai'i Cancer Center researchers used "Big Data" to discover potential cancer biomarkers, a panel of six long intergenic non-coding RNAs (lincRNAs), for the diagnosis of all types of cancers including lung, breast, prostate, liver and ovarian cancers.
Protecting Privacy in Genomic Databases
System helps ensure databases used in medical research will not leak patients’ personal information.
Algorithm To Find Precise Cancer Treatments For Patients Developed
The JAMMIT algorithm could help predict which patients will benefit most from chemotherapy.
Depression Genetics Insight from Crowd-Sourced Data
Genome sites liked to depression have been discovered from data shared by people who had purchased their genetic profiles online.
Detecting Hazardous Chemicals in Complex Mixtures
Researchers are pioneering a new chemical substance analyis software technique that could increase illicit substance detection.
Researchers Develop Software That Could Facilitate Drug Development
AptaTRACE can identify aptamers, potentially speed drug advancement.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!